Advertisement

Pharmaceutical Chemistry Journal

, Volume 52, Issue 12, pp 1011–1015 | Cite as

In Vitro Evaluation of Drug Content in and Drug Release Kinetics from Stents with Different Types of Polymer Coating

  • A. I. Prostyakova
  • D. I. Zybin
  • D. V. KapustinEmail author
Article
  • 38 Downloads

Drug elution profiles must be studied in vitro to optimize a polymer-drug formulation during development of drug-eluting stents (DESs). Results from HPLC assays of drug contents and elution kinetics from a biodegradable sirolimus coating and a stable zotarolimus coating on coronary DESs are presented. Drug contents were assessed for crimped stents on the delivery system and expanded stents. The drug coating morphology and elution kinetics were demonstrated to be associated. Significant coating morphological defects were shown to cause deviations in the drug elution profile.

Keywords

sirolimus zotarolimus drug-eluting stent HPLC drug-polymer coating 

References

  1. 1.
    J. Iqbal, J. Gunn, and P. W. Serruys, Br. Med. Bull., 106, 193 – 211 (2013).CrossRefGoogle Scholar
  2. 2.
    K. D. Rizas and J. Mehilli, Circulation: Cardiovascular Interventions, 9(6) (2016); URL: http://circinterventions.ahajournals.org/content/9/6/e002943 (accessed Mar. 14, 2018).
  3. 3.
    Medtronic. Resolute Integrity Zotarolimus-Eluting Coronary Stent System. Instructions for Use; URL: https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110013S005c.pdf (accessed Mar. 14, 2018).
  4. 4.
    A. N. Kudryashov, D. V. Trebushat, V. V. Verin, and V. L. Vorob’ev, Patol. Krovoobrashch. Kardiokhir., 21(1), 37 – 43 (2017).CrossRefGoogle Scholar
  5. 5.
    M. W. Basalus, M. Joner, C. von Birgelen, and R. A. Byrne, EuroIntervention, 9, 302 – 305 (2013).CrossRefGoogle Scholar
  6. 6.
    D. Kapustin, T. Dmitrieva, and A. Rashkovskiy, Interv. Cardiol., 9(3), 89 – 105 (2017).CrossRefGoogle Scholar
  7. 7.
    D. Kapustin, N. Orlinskaya, and K. Kulakova, Interv. Cardiol., 10(1), 1 – 7 (2017).Google Scholar
  8. 8.
    Z. Islambulchilar, S. Ghanbarzadeh, S. Emami, et al., Adv. Pharm. Bull., 2(2), 135 – 139 (2012).Google Scholar
  9. 9.
    B. C. Sallustio, B. D. Noll, and R. G. Morris, Clin. Biochem., 44(2 – 3), 231 – 236 (2011).CrossRefGoogle Scholar
  10. 10.
    Y. W. Chen, M. L. Smith, M. Sheets, et al., J. Cardiovasc. Pharmacol., 49(4), 228 – 235 (2007).CrossRefGoogle Scholar
  11. 11.
    I. T. Meredith, S. Worthley, R. Whitbourn, et al., EuroIntervention, 3(1), 50 – 53 (2007).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. I. Prostyakova
    • 1
  • D. I. Zybin
    • 2
  • D. V. Kapustin
    • 1
    Email author
  1. 1.M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussian Federation
  2. 2.Institute of Fine Chemical TechnologiesMoscow Technological UniversityMoscowRussia

Personalised recommendations